BioVie’s Phase 2 Trial Fully Enrolled to Test Its Oral Therapy NE3107
BioVie has completed enrollment for a Phase 2 clinical trial evaluating the safety and efficacy of its experimental oral therapy NE3107 in people with Parkinson’s disease. “To date, we have seen no drug-related adverse events [side effects],” Cuong Do, BioVie’s president and CEO, said in a company press…